Clinical Research Directory
Browse clinical research sites, groups, and studies.
PSMA PET for the Staging and Management of Hepatocellular Carcinoma
Sponsor: VA Office of Research and Development
Summary
This prospective, single-center study evaluates the clinical utility of F18-Piflufolastat (PSMA) PET/CT when added to conventional cross-sectional imaging for patients with suspected or confirmed hepatocellular carcinoma (HCC). The study aims to determine whether PSMA PET/CT improves diagnostic accuracy for indeterminate liver lesions (LI-RADS 3 and 4), enhances staging precision in treatment-naïve patients, and provides more accurate assessment of treatment response in patients undergoing locoregional therapy (LRT). The goal is to assess how PSMA PET/CT may impact clinical decision-making, staging, and management of HCC across multiple stages of disease.
Official title: Addition of F18-Piflufolastat PET/CT to Cross-Sectional Imaging for the Staging and Management of Hepatocellular Carcinoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
90
Start Date
2024-09-19
Completion Date
2028-09-30
Last Updated
2026-06-26
Healthy Volunteers
No
Conditions
Locations (2)
VA Greater Los Angeles Healthcare System, West Los Angeles, CA
West Los Angeles, California, United States
Miami VA Healthcare System, Miami, FL
Miami, Florida, United States